Oyster_Point_Social.jpg
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights
August 05, 2020 07:00 ET | Oyster Point Pharma, Inc.
OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease (DED) Planned for Q4 2020Cash and Cash Equivalents of $226.7 million as...
Oyster_Point_Social.jpg
Oyster Point Pharma to Report Second Quarter 2020 Financial Results on August 5, 2020
July 31, 2020 16:01 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., July 31, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 19, 2020 18:08 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock
May 15, 2020 02:01 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...
Oyster_Point_Social.jpg
Oyster Point Pharma Proposed Public Offering of Common Stock
May 12, 2020 16:20 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...
Oyster_Point_Social.jpg
Oyster Point Pharma Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
May 11, 2020 06:05 ET | Oyster Point Pharma, Inc.
ONSET-2 met the prespecified primary endpoint in both doses tested, demonstrating statistically significant improvement in Schirmer’s score from baseline to Week 4 in subjects receiving OC-01 nasal...
Oyster_Point_Social.jpg
Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights
May 11, 2020 06:00 ET | Oyster Point Pharma, Inc.
Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ONSET-2 Data Enables NDA Submission in 2H 2020 Cash and Cash...
Oyster_Point_Social.jpg
Oyster Point Pharma to Report First Quarter 2020 Financial Results on May 11, 2020
May 04, 2020 16:05 ET | Oyster Point Pharma, Inc.
PRINCETON, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster_Point_Social.jpg
Oyster Point Pharma Completes Enrollment in ONSET-2 Pivotal Phase 3 Clinical Trial of OC-01 Nasal Spray for Dry Eye Disease and Provides COVID-19 Business Update
March 30, 2020 07:30 ET | Oyster Point Pharma, Inc.
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020             NDA Submission Expected During 2H 2020 PRINCETON, N.J., March 30, 2020 (GLOBE NEWSWIRE) --  Oyster Point Pharma,...
Oyster_Point_Social.jpg
Oyster Point Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
February 27, 2020 16:01 ET | Oyster Point Pharma, Inc.
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 Cash and Cash Equivalents of $139.1 million as of December 31, 2019 Conference Call and Webcast Scheduled for 4:30 pm ET PRINCETON, N.J.,...